Company profile for Revolution Medicines

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on RAS and mTOR signaling pathways. We are utilizing our deep understanding of genetic drivers and adaptive resistance mechanisms in cancer, coupled with robust drug discovery and medicinal chemistry capabil...
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on RAS and mTOR signaling pathways. We are utilizing our deep understanding of genetic drivers and adaptive resistance mechanisms in cancer, coupled with robust drug discovery and medicinal chemistry capabilities, to build a portfolio of compounds that inhibit critical signaling nodes within the RAS and mTOR pathways.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
700 Saginaw Drive Redwood City, CA 94063
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/05/3181911/0/en/Revolution-Medicines-Reports-Third-Quarter-2025-Financial-Results-and-Update-on-Corporate-Progress.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180870/0/en/Revolution-Medicines-to-Participate-in-November-2025-Investor-Conferences.html

GLOBENEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/10/29/3176847/0/en/Revolution-Medicines-to-Report-Financial-Results-for-Third-Quarter-2025-After-Market-Close-on-November-5-2025.html

GLOBENEWSWIRE
29 Oct 2025

https://www.globenewswire.com/news-release/2025/10/27/3174539/0/en/Revolution-Medicines-RAS-ON-Multi-Selective-Inhibitor-Daraxonrasib-Granted-U-S-FDA-Orphan-Drug-Designation-in-Pancreatic-Cancer.html

GLOBENEWSWIRE
27 Oct 2025

https://www.globenewswire.com/news-release/2025/10/22/3171363/0/en/Revolution-Medicines-to-Present-Updated-Elironrasib-Safety-and-Efficacy-Data-in-Patients-with-KRAS-G12C-Non-Small-Cell-Lung-Cancer-Following-Treatment-with-a-KRAS-OFF-G12C-Inhibito.html

GLOBENEWSWIRE
22 Oct 2025

https://www.globenewswire.com/news-release/2025/10/17/3168413/0/en/Revolution-Medicines-Awarded-Voucher-for-Daraxonrasib-RMC-6236-Under-FDA-Commissioner-s-National-Priority-Voucher-Pilot-Program.html

GLOBENEWSWIRE
16 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty